BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed BIOA catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:a639ae2030bd7f674c40@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:BIOA P2 readout (est.): QUELL-CV
DESCRIPTION:A Phase 2 Study to Evaluate the Pharmacodynamics\, Safety and T
 olerability of BGE-102 in Participants With Obesity and Cardiovascular Ris
 k Factors\nNCT07656727 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: BioAge 
 Labs\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nTicker BIOA (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT07656727\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07656727
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
